With a view to display the latest technologies and products in the bio pharmaceutical field, Biotech China, one of the major Chinese biotech exhibition and conference, will be oranising the 2014 Biotech China from May 14 to16 in Nanjing, China. Through this event they plan to attract exhibitors and participants from across the globe by setting up business oriented fringe programmes.

Built in economically developed areas and close to talents pools, industrial parks are playing an essential and indispensable role as the carrier cum incubator for start-ups and SMEs in the development of the new emerging bio pharmaceutical industry in China. Featured with extensive capital invest, high risk, and long research and development (R&D) circle, among others, developing bio pharmaceutical industry requires high-tech scientific infrastructure and sustainable human resource for R&D.

Biotech China will be an excellent opportunity to meet the key players in the Chinese and international bio industrial parks and incubator scenes. Bio Alps from Switzerland and clusters from other countries will also be present and participate in the first China Summit Forum on Bio-Medicine Industrial Park Development on the second day of the exhibition.

The participating industrial parks include Nanjing Zhongshan Life Science Park, Nanjing Biotech and Pharmaceutical Valley, Jiangsu Life Science & Technology Innovation Park, Wuhan National Bio Industry Base (BioLake), Shandong International Biotechnology Park, Beijing Yizhuang Biomedical Park, Chengdu Hi-Tech Industrial Development Zone, as well as Bio Alps.

Taking advantage of the new FTA between Switzerland and China, Bio Alps, the life science cluster of Western Switzerland, will lead a delegation of eight Swiss companies to 2014 Biotech China. Bio Alps promotes synergies between academia, entrepreneurs, investors, authorities and new businesses to translate ideas into new products and bring new technologies to market.

US Gene Synthesis Heads CROs at Biotech China GenScript, the largest gene synthesis provider in the US., and a leading biology CRO in the world, has recently confirmed its participation at 2014 Biotech China. GenScript is a leading biology CRO focusing exclusively on early drug discovery and development services. Built on an assembly-line mode, one-stop solution, continuous improvement, and stringent IP protection, GenScript provides a comprehensive portfolio of services that include Bio-Reagent, Bio-Assay, Lead Optimisation, and Antibody Drug Development which can be effectively integrated into a value chain and operations. The company develops pre-clinical drug candidates time-efficiently and cost-effectively.